...Katarzyna Kapica-Topczewska; Francois Collin; Joanna Tarasiuk; Agata Czarnowska; Monika Chorąży; Anna Mirończuk; Jan Kochanowicz; Alina Kułakowska Introduction: Presence of anti-JC-virus antibodies (JCVAbs) is associated with the increased risk of natalizumab (NAT)-related progressive multifocal...

... studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). Methods: Multicenter, observational study, in which, information of 388 patients randomly selected and treated with FIN or NTZ in routine clinical practice...

... rebound in patients discontinuing natalizumab (NTZ). Methods: Twenty-one patients with relapsing-remitting multiple sclerosis (RRMS) treated with NTZ for ≥1 year and who switched to DMDs (glatiramer acetate [GA] or interferon) were followed up for 12 months in clinical practice. Clinical outcomes after...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Natalizumab Cohort study Historical Multiple sclerosis Interferon-beta Fingolimod Glatiramer acetate Multiple sclerosis (MS...

..., corticosteroids and plasma exchanges are validated and widely used. A few immunosuppressive drugs have been tried, but they had little efficiency. Methods: We describe three CIDP patients treated by Natalizumab (acting against cellular adhesion and T-cell migration) after a failure of the validated treatments...

...Álvaro Cobo-Calvo; Laura Bau; Elisabet Matas; Lucía Romero-Pinel; M. Alba Mañé Martínez; Carles Majós; Sergio Martínez Yélamos Introduction: We evaluated the effectiveness of natalizumab in patients with highly active, relapsing-remitting multiple sclerosis (HA-RRMS) to identify baseline predictors...

...Alberto Gajofatto; Maria Rachele Bianchi; Luciano Deotto; Maria Donata Benedetti Background: It is unclear whether natalizumab and fingolimod have analogous efficacy for relapsing-remitting multiple sclerosis (RRMS). Objective: To compare the outcome of RRMS patients treated with either therapy...

... sclerosis (MS) treated with natalizumab. Methods: Walking speed, stride length and stride time during a dual task (walking while forward counting, backward counting, semantic fluency, and phonemic fluency), a single walking task, and a detailed neuropsychological assessment were prospectively measured...

... natalizumab is apt to improve cognitive functions and mood in 29 patients tested psychometrically while under treatment for 6 months. We found improvements in some measures of attention, memory, mood, and well-being, but no deterioration, although patients suffered from their diseases for more than 10 years...

...Matthias Reinhard; Bernhard Rosengarten; Luise Kirchhoff; Andreas Hetzel; Sebastian Rauer Background: Natalizumab inhibits adherence of leukocytes to the cerebral endothelium. Since leukocytes play a role in regulating vascular tone, natalizumab may also affect cerebral vasoregulation. The aim...

...Norman Putzki; Manoj Kumar Baranwal; Barbara Tettenborn; Volker Limmroth; Ernst Kreuzfelder Background: Natalizumab is a humanized monoclonal antibody directed against very late activation antigen 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis. Blockade of VLA-4...

...Norman Putzki; Özgür Yaldizli; Robert Bühler; Guido Schwegler; Daniela Curtius; Barbara Tettenborn Background: Natalizumab has been recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with insufficient response to interferon-β or glatiramer acetate (disease...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Disease-modifying therapy Evidence-based medicine Interferon beta Glatiramer Natalizumab Therapeutic gain The treatment of relapsing-remitting multiple sclerosis...